Stroke-related translational research

Archives of Neurology

Volumn 68, Issue 9, 2011, Pages 1110-1123

  Caplan, Louis R ^a   Arenillas, Juan ^f   Cramer, Steven C ^c   Joutel, Anne ^g   Lo, Eng H ^b   Meschia, James ^d   Savitz, Sean ^e   Tournier Lasserve, Elizabeth ^g,h  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF VALLADOLID   (Spain)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 4; COLLAGEN TYPE 4 A1; DOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INOSINE; NICOTINIC ACID; NOTCH3 RECEPTOR; PHOSPHODIESTERASE V INHIBITOR; SEROTONIN; UNCLASSIFIED DRUG;

ARTERY DISSECTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CADASIL; CAVERNOUS HEMANGIOMA; CCM GENE; CCM2 GENE; CELL THERAPY; COL4A1 GENE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; KRITI1 GENE; NONHUMAN; NOTCH3 GENE; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; TREATMENT INDICATION;

ANIMALS; CEREBRAL ARTERIAL DISEASES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTATION; STROKE; TRANSLATIONAL RESEARCH;

EID: 79960748950     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.99     Document Type: Review

References (160)

1. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke. 2003;34(6):1364-1369. (Pubitemid 36693499)
2. Jood K, Ladenvall C, Rosengren A, Blomstrand C, Jern C. Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. Stroke. 2005;36(7):1383-1387. (Pubitemid 40967498)
3. Seshadri S, Beiser A, Pikula A, et al. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation. 2010;121(11):1304-1312.
4. Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med. 2009;360(17):1718-1728.
5. International Stroke Genetics Consortium; Wellcome Trust Case-Control Consortium 2. Failure to validate association between 12p13 variants and ischemic stroke. N Engl J Med. 2010;362(16):1547-1550.
6. Debette S, Bis JC, Fornage M, et al. Genome-wide association studies of MRIdefined brain infarcts: meta-analysis from the CHARGE Consortium. Stroke. 2010;41(2):210-217.
7. Anderson CD, Biffi A, Rost NS, Cortellini L, Furie KL, Rosand J. Chromosome 9p21 in ischemic stroke: population structure and meta-analysis. Stroke. 2010; 41(6):1123-1131.
8. Gretarsdottir S, Thorleifsson G, Manolescu A, et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008;64(4):402-409.
9. Lemmens R, Buysschaert I, Geelen V, et al International Stroke Genetics Consortium. The association of the 4q25 susceptibility variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology. Stroke. 2010;41(9):1850-1857.
10. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8(7):643-653.
11. Ruchoux MM, Guerouaou D, Vandenhaute B, Pruvo JP, Vermersch P, Leys D. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol. 1995;89(6):500-512.
12. Belin de Chantemèle EJ, Retailleau K, Pinaud F, et al. Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries. Arterioscler Thromb Vasc Biol. 2008;28(12):2216-2224.
13. Domenga V, Fardoux P, Lacombe P, et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 2004;18(22):2730-2735. (Pubitemid 39507766)
14. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996; 383(6602):707-710. (Pubitemid 26360644)
15. Monet-Leprêtre M, Bardot B, Lemaire B, et al. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Brain. 2009;132(pt 6):1601-1612.
16. Joutel A, Vahedi K, Corpechot C, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350(9090):1511- 1515. (Pubitemid 28036555)
17. Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG. De novo mutation in the Notch3 gene causing CADASIL. Ann Neurol. 2000;47(3):388-391. (Pubitemid 30141853)
18. Coto E, Menéndez M, Navarro R, García-Castro M, Alvarez V. A new de novo Notch3 mutation causing CADASIL. Eur J Neurol. 2006;13(6):628-631. (Pubitemid 43873635)
19. Joutel A, Favrole P, Labauge P, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001;358(9298):2049- 2051. (Pubitemid 34084832)
20. Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 2000;105(5):597-605. (Pubitemid 30146506)
21. Lesnik Oberstein SA, Van Duinen SG, Van den Boom R, et al. Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. Acta Neuropathol. 2003;106(2):107-111. (Pubitemid 36869243)
22. Dichgans M, Ludwig H, Müller-Höcker J, Messerschmidt A, Gasser T. Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet. 2000;8(4):280-285. (Pubitemid 30336181)
23. Opherk C, Duering M, Peters N, et al. CADASIL mutations enhance spontaneous multimerization of NOTCH3. Hum Mol Genet. 2009;18(15):2761-2767.
24. Joutel A, Monet-Leprêtre M, Gosele C, et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest. 2010;120(2):433-445.
25. Ruchoux MM, Domenga V, Brulin P, et al. Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.AmJ Pathol. 2003;162(1):329-342. (Pubitemid 36042015)
26. Brass SD, Smith EE, Arboleda-Velasquez JF, Copen WA, Frosch MP. Case records of the Massachusetts General Hospital: case 12-2009: a 46-year-old man with migraine, aphasia, and hemiparesis and similarly affected family members. N Engl J Med. 2009;360(16):1656-1665.
27. Tikka S, Mykkänen K, Ruchoux MM, et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain. 2009;132(pt 4):933-939.
28. Arnold S, Buchanan DD, Barker M, et al. Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat. 2009;30(5):757-770.
29. Haritunians T, Boulter J, Hicks C, et al. CADASIL Notch3 mutant proteins localize to the cell surface and bind ligand. Circ Res. 2002;90(5):506-508. (Pubitemid 34640899)
30. Monet M, Domenga V, Lemaire B, et al. The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo. Hum Mol Genet. 2007;16(8):982-992. (Pubitemid 47062741)
31. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling pathway. Am J Hum Genet. 2004;74(2):338-347. (Pubitemid 38168621)
32. Karlström H, Beatus P, Dannaeus K, Chapman G, Lendahl U, Lundkvist J. A CADASIL-mutated Notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Proc Natl Acad Sci U S A. 2002;99(26):17119-17124. (Pubitemid 36034108)
33. Peters N, Opherk C, Zacherle S, Capell A, Gempel P, Dichgans M. CADASIL-associated Notch3 mutations have differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. Exp Cell Res. 2004;299(2):454-464. (Pubitemid 39179811)
34. Lundkvist J, Zhu S, Hansson EM, et al. Mice carrying a R142C Notch 3 knock-in mutation do not develop a CADASIL-like phenotype. Genesis. 2005;41(1):13-22. (Pubitemid 40269718)
35. Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7(4):310-318.
36. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab. 2008;7(6):476-484. (Pubitemid 351729202)
37. Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatalcerebral hemorrhage and porencephaly. Science. 2005;308(5725):1167- 1171. (Pubitemid 40696433)
38. Gould DB, Phalan FC, Van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006;354(14):1489-1496.
39. Vahedi K, Kubis N, Boukobza M, et al. COL4A1 mutation in a patient with sporadic, recurrent intracerebral hemorrhage. Stroke. 2007;38(5):1461-1464. (Pubitemid 46684145)
40. Plaisier E, Gribouval O, Alamowitch S, et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med. 2007;357(26):2687-2695.
41. Alamowitch S, Plaisier E, Favrole P, et al. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology. 2009;73(22):1873-1882.
42. Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke. 2010;41(8):e513- e518.
43. Mine M, Tournier-Lasserve E. Intracerebral hemorrhage and COL4A1 mutations, from preterm infants to adult patients. Ann Neurol. 2009;65(1):1-2.
44. Vahedi K, Boukobza M, Massin P, Gould DB, Tournier-Lasserve E, Bousser MG. Clinical and brain MRI follow-up study of a family with COL4A1 mutation. Neurology. 2007;69(16):1564-1568. (Pubitemid 350287139)
45. Breedveld G, De Coo RF, Lequin MH, et al. Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly. J Med Genet. 2006; 43(6):490-495. (Pubitemid 43927322)
46. Plaisier E, Chen Z, Gekeler F, et al. Novel COL4A1 mutations associated with HANAC syndrome: a role for the triple helical CB3[IV] domain. Am J Med Genet A. 2010;152A(10):2550-2555.
47. Coutts SB, Matysiak-Scholze U, Kohlhase J, Innes AM. Intracerebral hemorrhage in a young man. CMAJ. 2011;183(1):E61-E64.
48. Vahedi K, Massin P, Guichard JP, et al. Hereditary infantile hemiparesis, retinal arteriolar tortuosity, and leukoencephalopathy. Neurology. 2003;60(1):57-63. (Pubitemid 36070644)
49. Sibon I, Coupry I, Menegon P, et al. COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann Neurol. 2007;62(2):177-184. (Pubitemid 47546503)
50. Aguglia U, Gambardella A, Breedveld GJ, et al. Suggestive evidence for linkage to chromosome 13qter for autosomal dominant type 1 porencephaly. Neurology. 2004;62(9):1613-1615. (Pubitemid 38608208)
51. Coupry I, Sibon I, Mortemousque B, Rouanet F, Mine M, Goizet C. Ophthalmological features associated with COL4A1 mutations. Arch Ophthalmol. 2010;128(4):483-489.
52. Rouaud T, Labauge P, Tournier Lasserve E, et al. Acute urinary retention due to a novel collagen COL4A1 mutation. Neurology. 2010;75(8):747-749.
53. Shah S, Kumar Y, McLean B, et al. A dominantly inherited mutation in collagen IV A1 (COL4A1) causing childhood onset stroke without porencephaly. Eur J Pediatr Neurol. 2010;14(2):182-187.
54. Smit LM, Barth PG, Valk J, Njiokiktjien C. Familial porencephalic white matter disease in two generations. Brain Dev. 1984;6(1):54-58. (Pubitemid 14115084)
55. Van der Knaap MS, Smit LM, Barkhof F, et al. Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol. 2006;59(3):504-511. (Pubitemid 43358071)
56. Bilguvar K, DiLuna ML, Bizarro MJ, et al. COL4A1 mutation in preterm intraventricular hemorrhage. J Pediatr. 2009;155(5):743-745.
57. De Vries LS, Koopman C, Groenendaal F, et al. COL4A1 mutation in two pre-term siblings with antenatal onset of parenchymal hemorrhage. Ann Neurol. 2009;65(1):12-18.
58. Martin JJ, Hausser I, Lyrer P, et al. Familial cervical artery dissections: clinical, morphologic, and genetic studies. Stroke. 2006;37(12):2924-2929. (Pubitemid 44900810)
59. Schievink WI, Michels VV, Piepgras DG. Neurovascular manifestations of heritable connective tissue disorders: a review. Stroke. 1994;25(4):889-903. (Pubitemid 24111341)
60. Debette S, Markus HS. The genetics of cervical artery dissection: a systematic review. Stroke. 2009;40(6):e459-e466.
61. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673-680. (Pubitemid 30131419)
62. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377-1385. (Pubitemid 38529880)
63. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101-116. (Pubitemid 9164903)
64. Mayer SA, Rubin BS, Starman BJ, Byers PH. Spontaneous multivessel cervical artery dissection in a patient with a substitution of alanine for glycine (G13A) in the alpha 1 (I) chain of type I collagen. Neurology. 1996;47(2):552-556. (Pubitemid 26324060)
65. Labauge P, Denier C, Bergametti F, Tournier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurol. 2007;6(3):237-244. (Pubitemid 46228079)
66. Faurobert E, Albiges-Rizo C. Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction. FEBS J. 2010;277 (5):1084-1096.
67. Whitehead KJ, Chan AC, Navankasattusas S, et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases [published correction appears in Nat Med. 2009;15(4):462]. Nat Med. 2009;15(2):177-184.
68. Kleaveland B, Zheng X, Liu JJ, et al. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway [published correction appears in Nat Med. 2009;15(5):584]. Nat Med. 2009;15(2):169-176.
69. Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010;207(4):881-896.
70. Yadla S, Jabbour PM, Shenkar R, Shi C, Campbell PG, Awad IA. Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution. Neurosurg Focus. 2010;29(3):E4.
71. Li DY, Whitehead KJ. Evaluating strategies for the treatment of cerebral cavernous malformations. Stroke. 2010;41(10)(suppl):S92-S94.
72. Boulday G, Rudini N, Maddaluno L, et al. The effects of CCM2 invalidation are restricted to intense angiogenesis periods both in the central nervous system and in the eye. Paper presented at: 16th International Vascular Biology Meeting; June 20-24, 2010; Los Angeles, CA.
73. Guo S, Lo EH. Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke. 2009;40(3)(suppl):S4- S7.
74. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181-198.
75. Platel JC, Dave KA, Gordon V, Lacar B, Rubio ME, Bordey A. NMDA receptors activated by subventricular zone astrocytic glutamate are critical for neuroblast survival prior to entering a synaptic network. Neuron. 2010;65(6):859-872.
76. Lee SR, Kim HY, Rogowska J, et al. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci. 2006;26(13):3491-3495.
77. Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12(4):441-445.
78. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med. 2008;14(5):497-500. (Pubitemid 351655209)
79. Fisher M, Feuerstein G, Howells DW, et al STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244-2250.
80. Hachinski V, Donnan GA, Gorelick PB, et al. Stroke: working toward a prioritized world agenda. Stroke. 2010;41(6):1084-1099.
81. Ning MM, Sarracino DA, Kho AT, et al. Proteomic temporal profile of human brain endothelium after oxidative stress. Stroke. 2011;42(1):37-43.
82. Sideso E, Papadakis M, Wright C, et al. Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery. Transl Stroke Res. 2010;1:304-314.
83. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Invited article: searching for oracles? blood biomarkers in acute stroke. Neurology. 2009;73(5):393-399.
84. Hacke W, Donnan G, Fieschi C, et al ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.
85. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107(4):598-603. (Pubitemid 36176811)
86. Castellanos M, Sobrino T, Millán M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke. 2007;38(6):1855-1859. (Pubitemid 46847259)
87. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39(4):1121-1126. (Pubitemid 351440679)
88. Reynolds MA, Kirchick HJ, Dahlen JR, et al. Early biomarkers of stroke. Clin Chem. 2003;49(10):1733-1739. (Pubitemid 37194242)
89. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC; BRAIN Study Group. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke. 2009;40(1):77-85.
90. Baird AE. Blood genomics in human stroke. Stroke. 2007;38(2)(suppl):694- 698. (Pubitemid 46184244)
91. Laterza OF, Modur VR, Crimmins DL, et al. Identification of novel brain biomarkers. Clin Chem. 2006;52(9):1713-1721. (Pubitemid 44330705)
92. Maurer MH, Haux D, Sakowitz OW, Unterberg AW, Kuschinsky W. Identification of early markers for symptomatic vasospasm in human cerebral microdialysate after subarachnoid hemorrhage: preliminary results of a proteome-wide screening. J Cereb Blood Flow Metab. 2007;27(10):1675-1683. (Pubitemid 47476094)
93. Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of MicroRNAs in young stroke patients. PLoS One. 2009;4(11):e7689.
94. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Mödder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain. 2004;127(pt 7):1670-1677. (Pubitemid 38899419)
95. Flögel U, Ding Z, Hardung H, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008;118(2):140-148.
96. Maletić-Savatić M, Vingara LK, Manganas LN, et al. Metabolomics of neural progenitor cells: a novel approach to biomarker discovery. Cold Spring Harb Symp Quant Biol. 2008;73:389-401.
97. Klohs J, Steinbrink J, Bourayou R, et al. Near-infrared fluorescence imaging with fluorescently labeled albumin: a novel method for non-invasive optical imaging of blood-brain barrier impairment after focal cerebral ischemia in mice. J Neurosci Methods. 2009;180(1):126-132.
98. Cormode DP, Roessl E, Thran A, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology. 2010;256(3):774-782.
99. Amirbekian V, Aguinaldo JG, Amirbekian S, et al. Atherosclerosis and matrix metalloproteinases: experimental molecularMRimaging in vivo. Radiology. 2009;251(2):429-438.
100. Kim DE, Kim JY, Schellingerhout D, et al. Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging. Arterioscler Thromb Vasc Biol. 2010;30(3):449-456.
101. Janowski M, Walczak P, Date I. Intravenous route of cell delivery for treatment of neurological disorders: a meta-analysis of preclinical results. Stem Cells Dev. 2010;19(1):5-16.
102. Li Y, Chopp M. Marrow stromal cell transplantation in stroke and traumatic brain injury. Neurosci Lett. 2009;456(3):120-123.
103. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009;40(2):510-515.
104. Walczak P, Zhang J, Gilad AA, et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke. 2008;39(5):1569-1574.
105. Arbab AS, Janic B, Haller J, Pawelczyk E, LiuW, Frank JA. In vivo cellular imaging for translational medical research. Curr Med Imaging Rev. 2009;5(1):19-38.
106. Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005;103(1):38-45. (Pubitemid 43193932)
107. Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis. 2005;20(2):101-107. (Pubitemid 41160209)
108. Savitz SI, Misra V. Launching intravenous bone marrow cell trials for acute stroke. Regen Med. 2009;4(5):639-641.
109. Nudo RJ. Recovery after damage to motor cortical areas. Curr Opin Neurobiol. 1999;9(6):740-747.
110. Cramer SC, Chopp M. Recovery recapitulates ontogeny. Trends Neurosci. 2000; 23(6):265-271. (Pubitemid 30331113)
111. Carmichael ST, Archibeque I, Luke L, Nolan T, Momiy J, Li S. Growth-associated gene expression after stroke: evidence for a growth-promoting region in periinfarct cortex. Exp Neurol. 2005;193(2):291-311. (Pubitemid 40616180)
112. Wieloch T, Nikolich K. Mechanisms of neural plasticity following brain injury. Curr Opin Neurobiol. 2006;16(3):258-264. (Pubitemid 43949227)
113. Hacke W, Kaste M, Bluhmki E, et al ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317-1329.
114. Cramer SC. Repairing the human brain after stroke: II, restorative therapies. Ann Neurol. 2008;63(5):549-560.
115. Wolf SL, Winstein CJ, Miller JP, et al EXCITE Investigators. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA. 2006;296(17):2095- 2104.
116. Lo AC, Guarino PD, Richards LG, et al. Robot-assisted therapy for long-term upper-limb impairment after stroke. N Engl J Med. 2010;362(19):1772- 1783.
117. Grotta J, Bratina P. Subjective experiences of 24 patients dramatically recovering from stroke. Stroke. 1995;26(7):1285-1288.
118. Fisher M, Ratan R. New perspectives on developing acute stroke therapy. Ann Neurol. 2003;53(1):10-20. (Pubitemid 36083824)
119. Gladstone DJ, Black SE, Hakim AM; Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33(8):2123-2136. (Pubitemid 34840080)
120. Philip M, Benatar M, Fisher M, Savitz SI.Methodological quality of animal stud-ies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40(2):577-581.
121. Toth G, Albers GW. Use of MRI to estimate the therapeutic window in acute stroke: is perfusion-weighted imaging/diffusion-weighted imaging mismatch an EPITHET for salvageable ischemic brain tissue? Stroke. 2009;40(1):333-335.
122. Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol. 2009;8(3):261-269.
123. Riley JD, Le V, Der-Yeghiaian L, et al. Anatomy of stroke injury predicts gains from therapy. Stroke. 2011;42(2):421-426.
124. Cramer SC, Parrish TB, Levy RM, et al. Predicting functional gains in a stroke trial. Stroke. 2007;38(7):2108-2114. (Pubitemid 47012276)
125. Tardy J, Pariente J, Leger A, et al. Methylphenidate modulates cerebral post-stroke reorganization. Neuroimage. 2006;33(3):913-922. (Pubitemid 44584756)
126. Stinear CM, Barber PA, Smale PR, Coxon JP, Fleming MK, Byblow WD. Functional potential in chronic stroke patients depends on corticospinal tract integrity. Brain. 2007;130(pt 1):170-180. (Pubitemid 46026233)
127. Feuerstein GZ, Zaleska MM, Krams M, et al. Missing steps in the STAIR case: a TranslationalMedicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28(1):217-219.
128. Dromerick AW, Lang CE, Birkenmeier RL, et al. Very early constraint-induced movement during stroke rehabilitation (VECTORS): a single-center RCT. Neurology. 2009;73(3):195-201.
129. Cramer SC, Dobkin BH, Noser EA, Rodriguez RW, Enney LA. Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. Stroke. 2009; 40(9):3034-3038.
130. Adkins DL, Hsu JE, Jones TA. Motor cortical stimulation promotes synaptic plasticity and behavioral improvements following sensorimotor cortex lesions. Exp Neurol. 2008;212(1):14-28.
131. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 1982;217(4562):855-857. (Pubitemid 12042921)
132. García-Alías G, Barkhuysen S, Buckle M, Fawcett JW. Chondroitinase ABC treatment opens awindow of opportunity for task-specific rehabilitation. Nat Neurosci. 2009;12(9):1145-1151.
133. Kwakkel G. Impact of intensity of practice after stroke: issues for consideration. Disabil Rehabil. 2006;28(13-14):823-830.
134. Kwakkel G, Wagenaar RC, Twisk JW, Lankhorst GJ, Koetsier JC. Intensity of leg and arm training after primary middle-cerebral-artery stroke: a randomised trial. Lancet. 1999;354(9174):191-196. (Pubitemid 29329157)
135. Dobkin B. The Clinical Science of Neurologic Rehabilitation. New York, NY: Oxford University Press; 2003.
136. Van Peppen RP, Kwakkel G, Wood-Dauphinee S, Hendriks HJ, Van der Wees PJ, Dekker J. The impact of physical therapy on functional outcomes after stroke: what's the evidence? Clin Rehabil. 2004;18(8):833-862. (Pubitemid 39642264)
137. Cicerone KD, Dahlberg C, Malec JF, et al. Evidence-based cognitive rehabilitation: updated review of the literature from 1998 through 2002. Arch Phys Med Rehabil. 2005;86(8):1681-1692. (Pubitemid 41115836)
138. Bhogal SK, Teasell R, Speechley M. Intensity of aphasia therapy, impact on recovery. Stroke. 2003;34(4):987-993.
139. Jones TA, Chu CJ, Grande LA, Gregory AD. Motor skills training enhances lesion-induced structural plasticity in the motor cortex of adult rats. J Neurosci. 1999;19(22):10153-10163. (Pubitemid 30226687)
140. Johansson BB. Brain plasticity and stroke rehabilitation: theWillis Lecture. Stroke. 2000;31(1):223-230. (Pubitemid 30035778)
141. Cramer SC. Repairing the human brain after stroke: I, mechanisms of spontaneous recovery. Ann Neurol. 2008;63(3):272-287. (Pubitemid 351499857)
142. McFadden E, Luben R, Wareham N, Bingham S, Khaw KT. Social class, risk factors, and stroke incidence in men and women: a prospective study in the European prospective investigation into cancer in Norfolk cohort. Stroke. 2009;40(4):1070-1077.
143. Smith J, Forster A, Young J; Cochrane Group for information provision after stroke. Cochrane review: information provision for stroke patients and their caregivers. Clin Rehabil. 2009;23(3):195-206.
144. Glass TA, Matchar DB, Belyea M, Feussner JR. Impact of social support on outcome in first stroke. Stroke. 1993;24(1):64-70. (Pubitemid 23014384)
145. Lai SM, Duncan PW, Keighley J, Johnson D. Depressive symptoms and independence in BADL and IADL. J Rehabil Res Dev. 2002;39(5):589-596. (Pubitemid 35388078)
146. Jönsson AC, Lindgren I, Hallström B, Norrving B, Lindgren A. Determinants of quality of life in stroke survivors and their informal caregivers. Stroke. 2005;36(4):803-808.
147. Mukherjee D, Levin RL, Heller W. The cognitive, emotional, and social sequelae of stroke: psychological and ethical concerns in post-stroke adaptation. Top Stroke Rehabil. 2006;13(4):26-35. (Pubitemid 44748615)
148. Kleim JA, Chan S, Pringle E, et al. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci. 2006;9(6):735-737.
149. Siironen J, Juvela S, Kanarek K, Vilkki J, Hernesniemi J, Lappalainen J. The Met allele of the BDNF Val66Met polymorphism predicts poor outcome among survivors of aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(10):2858- 2860.
150. Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral haemorrhage. Lancet. 1995;346(8974):575.
151. Niskakangas T, Ohman J, Niemelä M, Ilveskoski E, Kunnas TA, Karhunen PJ. Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage: a preliminary study. Stroke. 2001;32(5):1181-1184. (Pubitemid 32825806)
152. Volpe BT, Ferraro M, Lynch D, et al. Robotics and other devices in the treatment of patients recovering from stroke. Curr Neurol Neurosci Rep. 2005;5(6):465-470. (Pubitemid 41700666)
153. Scheidtmann K, Fries W, Müller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001;358(9284):787-790. (Pubitemid 32868727)
154. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke: further evidence. Stroke. 1995;26(12):2254-2259.
155. Gresham G, Duncan P, Stason W, et al. Post-Stroke Rehabilitation. Rockville, MD: US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1995.
156. Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. Stroke. 2002;33(11):2718-2721. (Pubitemid 35266447)
157. Hier DB, Mondlock J, Caplan LR. Recovery of behavioral abnormalities after right hemisphere stroke. Neurology. 1983;33(3):345-350. (Pubitemid 13155767)
158. Marshall RS, Perera GM, Lazar RM, Krakauer JW, Constantine RC, DeLaPaz RL. Evolution of cortical activation during recovery from corticospinal tract infarction. Stroke. 2000;31(3):656-661. (Pubitemid 30131651)
159. Markgraf CG, Green EJ, Hurwitz BE, et al. Sensorimotor and cognitive consequences of middle cerebral artery occlusion in rats. Brain Res. 1992;575 (2):238-246.
160. Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents. Stroke. 2007;38(4):1393-1395. (Pubitemid 351664265)